Premium Nahrungsergänzungsmittel | artgerecht

Neuroprotective Agent: Definition, Mechanism and Use

A neuroprotective agent is a substance or therapy that protects nerve cells from damage or death. It is used in the treatment of neurological diseases.

Regular tips about health Regular tips about health

Things worth knowing about "Neuroprotective Agent"

A neuroprotective agent is a substance or therapy that protects nerve cells from damage or death. It is used in the treatment of neurological diseases.

What is a Neuroprotective Agent?

The term neuroprotective agent (also called a neuroprotectant) refers to substances, drugs, or therapeutic strategies designed to protect neurons (nerve cells) from damage, promote their survival, and slow or prevent the progressive loss of neurological function. The concept of neuroprotection is central to modern neurology and neuroscience, particularly in conditions where nerve cells are gradually destroyed by disease processes.

Mechanism of Action

Neuroprotective agents work through a variety of mechanisms to counteract neuronal damage. The most important include:

Inhibition of excitotoxicity: Neurons can be damaged by excessive activation of glutamate receptors. Neuroprotective agents can block this process.
Reduction of oxidative stress: Free radicals cause damage to nerve cells. Antioxidant neuroprotectants neutralize these harmful molecules.
Anti-inflammatory effects: Chronic brain inflammation (neuroinflammation) contributes to neuronal damage. Anti-inflammatory substances can counteract this process.
Promotion of cell survival: Growth factors such as BDNF (Brain-Derived Neurotrophic Factor) and NGF (Nerve Growth Factor) support neuronal survival and regeneration.
Stabilization of mitochondrial function: Mitochondria supply energy to neurons. Neuroprotective agents can stabilize mitochondrial function and prevent cell death.
Inhibition of apoptosis: They can inhibit the programmed cell death (apoptosis) of neurons.

Areas of Application

Neuroprotective agents are researched and used in a wide range of neurological conditions, including:

Parkinson's Disease: Substances such as MAO-B inhibitors (e.g., selegiline, rasagiline) are intended to slow the degeneration of dopaminergic neurons.
Alzheimer's Disease: Acetylcholinesterase inhibitors and NMDA receptor antagonists (e.g., memantine) exert neuroprotective effects.
Stroke (ischemia): After a stroke, neuroprotective measures aim to rescue neurons in the so-called penumbra, the zone of tissue at risk surrounding the infarct core.
Multiple Sclerosis: Immunomodulatory therapies indirectly protect nerve fibers from demyelination and axonal damage.
Amyotrophic Lateral Sclerosis (ALS): Riluzole is an approved neuroprotective drug that inhibits glutamate-mediated excitotoxicity.
Traumatic Brain Injury: Various approaches aim to limit secondary neuronal damage following trauma.

Key Neuroprotective Substances and Examples

Among the best-known and clinically used neuroprotective substances are:

Riluzole: Approved for ALS; inhibits glutamate release.
Memantine: NMDA receptor antagonist used in Alzheimer's disease.
Selegiline and Rasagiline: MAO-B inhibitors used in Parkinson's disease.
Vitamin E and other antioxidants: Investigated for neuroprotective properties in various conditions.
Erythropoietin (EPO): Shows neuroprotective effects in studies on stroke and premature birth.
Cannabinoids: Under investigation for neuroprotective properties in several neurological diseases.

State of Research and Challenges

Despite promising results in laboratory and animal studies, the clinical development of neuroprotective agents faces significant challenges. Many substances that proved effective in animal models have failed to demonstrate efficacy in human clinical trials. Reasons for this include the complexity of the human nervous system, the difficulty of crossing the blood-brain barrier, and the often delayed initiation of treatment. Research in this field is highly active, and the development of new neuroprotective strategies is considered one of the most important challenges in modern neurology.

References

Dirnagl, U., Iadecola, C., Moskowitz, M. A. (1999): Pathobiology of ischaemic stroke: an integrated view. In: Trends in Neurosciences, 22(9), 391-397.
Przedborski, S., Vila, M., Jackson-Lewis, V. (2003): Neurodegeneration: What is it and where are we? In: Journal of Clinical Investigation, 111(1), 3-10.
World Health Organization (WHO): Neurological Disorders: Public Health Challenges. WHO Press, Geneva, 2006.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.